All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

What the FDA records show about Ozempic supply, and why some pharmacies still run out

The FDA lists no Ozempic shortage; it was declared resolved on February 21, 2025. See the timeline, why individual pharmacies still run out, and how to check.

By FormBlends Editorial Research|Reviewed by FormBlends Medical Team||
In This Article

This article is part of our Safety & Quality collection. See also: Peptide Guides | GLP-1 Guides

See your personalized options in about 2 minutes. Free and private. See my options →
  • The FDA removed semaglutide from the Drug Shortages Database on February 21, 2025. As of May 2026, no active shortage is listed.
  • The shortage that began in early 2022 was driven by fill-finish capacity, not active ingredient supply. Adding pen-assembly capacity took multiple years.
  • Novo Nordisk announced major capacity expansions through 2023 and 2024 in Kalundborg (Denmark), Chartres (France), and Clayton (North Carolina), and Novo Holdings completed its acquisition of Catalent at the end of 2024.
  • The end of the shortage substantially narrowed the FDA-recognized basis for broad compounding of semaglutide under section 503A.
  • Local pharmacy-level supply issues can still happen, but the national shortage status is resolved.

No national Ozempic shortage is listed by the FDA as of May 2026. The FDA Drug Shortages Database removed semaglutide injection on February 21, 2025, after Novo Nordisk demonstrated sustained production capable of meeting demand. Localized supply variation at individual pharmacies can still occur, but the multi-year shortage that began in 2022 is no longer in effect.

  1. The current FDA status
  2. The full shortage timeline (2022 to 2025)
  3. Why the shortage happened
  4. What changed to resolve it
  5. What "shortage resolved" actually means at the pharmacy counter
  6. How the compounding landscape shifted after resolution
  7. What could cause a future shortage
  8. How to verify current supply yourself
  9. What this means for patients
  10. FAQ
  11. Sources

Where Ozempic stands in the FDA Drug Shortages Database

The FDA Drug Shortages Database is the authoritative public source for shortage information. As of May 2026, semaglutide injection is not listed. The database shows the resolution date as February 21, 2025, with all doses (Ozempic 0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg; Wegovy 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) marked as available.

Wegovy and Ozempic share the same active ingredient and the same FDA shortage classification. When semaglutide was removed from the shortage list, both brands were affected.

Ozempic shortage timeline from first listing to resolution

DateEvent
March 2022Novo Nordisk reported supply constraints for Wegovy; FDA shortage listing followed.
August 2022Ozempic added to the FDA shortage list as off-label weight-loss prescribing surged.
2023Compounded semaglutide proliferated through telehealth platforms under shortage-tolerance rules; Novo Nordisk announced capacity expansion at Kalundborg and Clayton.
September 2023FDA added ileus as a postmarketing adverse reaction to the semaglutide label, separate from the shortage issue.
October 2024Tirzepatide (Mounjaro, Zepbound) removed from the FDA shortage list, foreshadowing semaglutide resolution.
December 2024Novo Holdings completed its acquisition of Catalent, adding fill-finish capacity.
February 21, 2025FDA removed semaglutide injection from the shortage list.
March-April 2025Transition period for compounding; some state-licensed compounding pharmacies wound down semaglutide preparation.
May 2026Supply stable; no national shortage in effect.

What drove the semaglutide supply crunch: Wegovy demand and fill-finish limits

Several forces compounded.

Get medications from a trusted source

FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.

Start Free Assessment →

Force 1: Wegovy approval (June 2021) added obesity demand. The same molecule that had been selling steadily for diabetes since 2017 suddenly had a new patient population, often prescribed at higher doses.

Force 2: Off-label prescribing of Ozempic for weight loss exploded. Clinicians prescribed Ozempic off-label for patients without diabetes, drawing supply away from diabetes patients who depended on it.

Force 3: Social-media virality accelerated demand. The semaglutide story moved through TikTok, Twitter, and traditional media in 2022 and 2023, expanding awareness beyond the population that meets clinical criteria.

Force 4: Fill-finish capacity could not scale fast. The bottleneck was pen assembly. Adding fill-finish capacity required years of build-out and regulatory qualification.

The active ingredient itself, semaglutide drug substance, was not the limiting factor. Novo Nordisk's Kalundborg API plant produced enough drug substance to support production growth before fill-finish capacity could catch up. The mismatch between API capacity and fill-finish capacity drove the prolonged shortage.

Three pillars behind the end of the semaglutide shortage

The resolution had three pillars.

Pillar 1: Novo Nordisk built capacity. The Clayton, North Carolina facility added fill-finish lines through 2023 and 2024. Chartres in France expanded. Kalundborg continued to grow.

Pillar 2: Novo Holdings acquired Catalent. The December 2024 close of the Catalent acquisition gave Novo Holdings (and through it, Novo Nordisk) access to substantial additional fill-finish capacity that could be deployed for semaglutide production.

Pillar 3: Demand stabilized. After the initial surge, demand growth moderated as cash-pay markets saturated, payer coverage decisions stabilized, and the novelty factor declined. The capacity-to-demand ratio improved from both sides.

By early 2025, Novo Nordisk could demonstrate to the FDA that production was sustainably meeting demand across all dose strengths. The FDA then resolved the shortage classification on February 21, 2025.

Why a resolved shortage still means some empty pharmacy shelves

Resolution at the FDA level means the agency no longer considers the supply situation a shortage. It does not mean every pharmacy has every dose in stock on every day.

Patients may still encounter:

  • Periodic stock-outs at individual pharmacies that can be resolved by transfer to another pharmacy in the area.
  • Specific NDC codes (particular dose and pen configurations) being temporarily unavailable.
  • Distribution-level delays of a few days for specific lot codes.
  • Pharmacy-level prioritization of patients with existing prescriptions over new starters during transition periods.

These pharmacy-level fluctuations are part of normal pharmaceutical distribution and do not reflect a national shortage.

Compounded semaglutide after the FDA resolution

Compounded semaglutide became widely available during the shortage period because FDCA section 503A allows state-licensed compounding pharmacies to compound drugs that are on the FDA shortage list, in response to individual prescriptions.

The February 2025 resolution narrowed that basis.

  • Compounding under the "essentially a copy of an FDA-approved drug" exemption became substantially restricted.
  • Compounding pharmacies and telehealth platforms that had built businesses on shortage-tolerance compounding wound down or restructured.
  • Novo Nordisk pursued litigation against entities the company alleged continued to market compounded semaglutide as equivalent to Ozempic or Wegovy.
  • Some clinically specific compounding (such as preparation with a different active ingredient or formulation that addressed an individual patient's documented clinical need) remained possible under narrower rules.

Patients who had been receiving compounded semaglutide during the shortage often transitioned to brand-name Ozempic or Wegovy, switched to tirzepatide (Mounjaro or Zepbound), or discontinued therapy.

Scenarios that could bring semaglutide back to the shortage list

Several scenarios could push semaglutide back to the shortage list.

  1. New indications that materially expand demand. Approvals for additional cardiovascular, renal, or other indications could draw substantial new prescribing.
  2. Major payer policy shifts. Expanded Medicare or commercial coverage could pull large patient populations into the market on short timelines.
  3. A manufacturing disruption. An incident at Kalundborg, Clayton, or another major site could constrain output regionally or globally.
  4. A regulatory finding. An FDA inspection or compliance issue at a key facility could pause production temporarily.
  5. Geopolitical or trade events. Disruption to shipping lanes between API sites and fill-finish sites could create timing-driven shortages.

None of these are predicted, but each is plausible enough that "shortage cannot happen again" would be overconfident.

Where to look up live semaglutide supply

The best sources for live information are direct.

  • FDA Drug Shortages Database. Available at the FDA website; updated as manufacturers report changes.
  • American Society of Health-System Pharmacists (ASHP) Drug Shortages list. A parallel professional resource that sometimes reflects pharmacy-level perspective.
  • Your pharmacy. Pharmacy staff can check distributor inventory for specific NDCs in real time, often more accurately than national lists.
  • Novo Nordisk's supply update page. The manufacturer occasionally publishes supply status communications.

News coverage often lags real-time data. A pharmacy check is more reliable than a headline.

Practical steps for patients now that supply has recovered

The practical implications:

  • If your prescription has been on hold or you have been waiting for supply, supply is now generally available. Confirm with your pharmacy.
  • If you have been on compounded semaglutide, discuss with your clinician whether to transition to brand-name therapy.
  • If you were considering starting Ozempic or Wegovy, supply availability is no longer a major barrier; coverage and cost remain the principal constraints.
  • If you experience a pharmacy-level stock-out, check with another local pharmacy or your wholesaler-affiliated network before assuming a broader shortage.

Resolved versus abundant: coverage and capacity gaps

A balanced reading acknowledges that "no shortage" is not the same as "easy access."

  • Coverage is uneven. Insurance coverage of Wegovy varies; many patients without coverage cannot afford cash list prices.
  • Capacity has limits. Demand growth at historical rates could outpace capacity again over a few years.
  • Manufacturing concentration is high. Two companies (Novo Nordisk and Eli Lilly) supply the entire US GLP-1 market. Concentration creates systemic risk.
  • Global supply is uneven. Markets outside the United States and Europe have experienced delayed access; "resolved" status applies to specific markets and may not be globally uniform.

Calling the shortage over is correct. Calling supply abundant is not. The right framing is "supply is meeting current demand under current coverage."

Is there an Ozempic shortage right now?

No national shortage is listed by the FDA. Local pharmacy-level supply variation can occur but is not a shortage.

When did the FDA declare the Ozempic shortage over?

February 21, 2025.

What triggered the original Ozempic supply problem?

Demand growth from Wegovy approval and off-label Ozempic prescribing outpaced fill-finish capacity.

Is Wegovy back in supply too?

Yes. Wegovy shares the semaglutide shortage classification with Ozempic. Both are listed as resolved.

Is compounded semaglutide still an option after the shortage?

Discuss with your prescribing clinician. The shortage-tolerance basis for compounding narrowed after February 2025.

Can supply be checked online before filling a prescription?

The FDA Drug Shortages Database is the official source. Your pharmacy can check distributor-level stock for specific NDCs.

Is a second Ozempic shortage likely?

Possible but not predicted. Capacity has expanded; demand growth has moderated. The risk is lower than it was in 2022-2024.

Does a shortage ending lower the Ozempic price?

No direct mechanism. List prices are set by the manufacturer and not driven by shortage status. Coverage and rebate dynamics are the larger price levers.

  1. US Food and Drug Administration. Drug Shortages Database. Semaglutide injection resolution, February 21, 2025.
  2. US Food and Drug Administration. Drug Shortages Database. Tirzepatide injection resolution, October 2, 2024.
  3. Federal Food, Drug, and Cosmetic Act. Section 503A (compounding by licensed pharmacists).
  4. Novo Nordisk A/S. Annual Report 2024. Capacity disclosures.
  5. Novo Holdings. Catalent acquisition completion announcement, December 2024.
  6. American Society of Health-System Pharmacists. Drug Shortages Resource Center.
  7. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
  8. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
  9. US Food and Drug Administration. Ozempic and Wegovy Prescribing Information.
  10. FDA. Guidance for Industry: Compounding Animal and Human Drugs Under Section 503A of the FD&C Act. Current edition.

Platform Disclaimer. FormBlends provides general educational content about drug supply status. Live shortage status should be verified through the FDA Drug Shortages Database. This article is not a substitute for clinical care.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. After the February 2025 resolution of the semaglutide shortage, the legal and regulatory basis for compounding under FDCA section 503A narrowed substantially.

Results Disclaimer. Supply status applies to the national availability of FDA-approved products. Pharmacy-level availability and individual patient experience may differ from national status.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with either manufacturer.

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →
Is the Ozempic shortage over in FDA records and pharmacies?
FormBlends guide cover for Is the Ozempic shortage over in FDA records and pharmacies?.

Continue with decision-grade research

Compare the options behind this question

These pages separate verified facts, commercial terms, and unresolved claims so you can check the evidence before choosing a provider.

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Related treatment context

Is the Ozempic shortage over in FDA records and pharmacies? research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

Original tools and data

Use FormBlends tools and data

Compare provider prices, explore local access and check calculations using FormBlends tools and data.

Download the Medication Safety Checklist

A printable checklist for verifying pharmacy credentials, reading COAs, and safe injection practices.

Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded semaglutide first month $99, then $190 per month, shipping included.

Next Best Reads

Safety & Quality

Is There a Zepbound Shortage in 2026? Where Tirzepatide Supply Stands

No national Zepbound shortage is listed by the FDA as of May 2026. Includes 2026 evidence, safety boundaries, and what to verify with a licensed clinician.

Safety & Quality

The GLP-1 Supply Chain Explained: How the Shortage Happened, What Fixed It, What Compounding Did

GLP-1 shortages between 2022 and 2025 happened because demand for diabetes and obesity prescribing grew faster than fill-finish.

GLP-1 Weight Loss

Is Tirzepatide Going Away? FDA Shortage Status, Supply Chain Reality, and What Happens Next

No, tirzepatide is not going away. Current FDA shortage status, what happens to compounded versions when shortages end, and supply timeline through 2027.

Safety & Quality

Where Is Ozempic Manufactured? Mapping Novo Nordisk's Global Supply Chain

Where Is Ozempic Manufactured? Mapping Novo Nordisk's Global Supply Chain explained with current evidence and patient-safety context.

GLP-1 Weight Loss

Is Semaglutide Going Away? The 2026 Supply Reality, FDA Shortage Status, and What Happens Next

No, semaglutide is not going away. Brand-name and compounded versions remain available. Here's the FDA shortage timeline, supply reality, and what changes in 2026.

Peptide Therapy

FDA Drug Shortage Compounding Rules

The FDA drug shortage list has become one of the most important factors in access to compounded GLP-1 medications. This FDA drug shortage compounding resource covers the essential information you need to make informed decisions.

GLP-1 Weight Loss

Is There an Ozempic Patch? What's Real, What's a Scam, and What Works Instead

There is no FDA-approved Ozempic patch. Here's what the products being marketed as 'Ozempic patches' actually contain, and what the science says.

Quick Answers

Compounded Semaglutide Shortage Availability 2026

Compounded Semaglutide Shortage Availability 2026. Evidence-based answers from FormBlends, a physician-supervised telehealth weight loss clinic.

GLP-1 Weight Loss

Why There's No Ozempic Patch (and the 3 Transdermal GLP-1 Technologies Actually in Clinical Trials)

No Ozempic patch exists. Why semaglutide can't penetrate skin, what Novo Nordisk is actually testing, and the 3 transdermal GLP-1 systems in trials.

FormBlends for iPhone

Track your routine in the FormBlends app

Doses, schedules, reminders, meals and progress in one free iPhone app.

Free Tools

Calculators to support your weight loss journey.